Sophia C Souto1, Leonardo O Reis, Thais Palma, Paulo Palma, Fernandes Denardi. 1. Division of Urology, School of Medical Sciences, University of Campinas (Unicamp), Rua: Tessália Vieira de Camargo, 126, Cidade Universitária "Zeferino Vaz", Campinas, SP, CEP: 13083-887, Brazil.
Abstract
OBJECTIVE: To verify whether the combination of transcutaneous electrical neural stimulation (TENS) with oxybutynin in the treatment of women with overactive bladder (OAB) would be more effective than isolated treatments. METHODS: We randomized 75 women with OAB, in three groups: GI--30 min TENS, twice a week; GII--daily slow release 10 mg oxybutynin; and GIII--TENS + oxybutynin (multimodal); all for 12 weeks. Patients were evaluated with validated questionnaires International Consultation on Incontinence-Short Form (ICIQ-SF), International Consultation on Incontinence-OAB (ICIQ-OAB), Symptom bother, and 3-day Voiding diary at weeks 0, 12, and 24. RESULTS: The groups were similar before treatment. After treatment, all groups significantly improved in OAB symptoms and quality of life (QoL). At week 12, ICIQ-OAB scores were 5.9, 4.6, and 2.9, in groups I, II, and III, respectively, p = 0.01. At week 24, GI and GIII kept the scores of the end of treatment (week 12), while GII increased ICIQ-OAB from 4.6 to 9.2, p = 0.0001, ICIQ-SF from 9.8 to 13.3, p = 0.0006, and Symptom bother score from 3.4 to 7.0, p = 0.0001. CONCLUSIONS: The multimodal treatment was more effective and TENS alone or in association presented longer lasting results for improvement of clinical symptoms of OAB and QoL.
RCT Entities:
OBJECTIVE: To verify whether the combination of transcutaneous electrical neural stimulation (TENS) with oxybutynin in the treatment of women with overactive bladder (OAB) would be more effective than isolated treatments. METHODS: We randomized 75 women with OAB, in three groups: GI--30 min TENS, twice a week; GII--daily slow release 10 mg oxybutynin; and GIII--TENS + oxybutynin (multimodal); all for 12 weeks. Patients were evaluated with validated questionnaires International Consultation on Incontinence-Short Form (ICIQ-SF), International Consultation on Incontinence-OAB (ICIQ-OAB), Symptom bother, and 3-day Voiding diary at weeks 0, 12, and 24. RESULTS: The groups were similar before treatment. After treatment, all groups significantly improved in OAB symptoms and quality of life (QoL). At week 12, ICIQ-OAB scores were 5.9, 4.6, and 2.9, in groups I, II, and III, respectively, p = 0.01. At week 24, GI and GIII kept the scores of the end of treatment (week 12), while GII increased ICIQ-OAB from 4.6 to 9.2, p = 0.0001, ICIQ-SF from 9.8 to 13.3, p = 0.0006, and Symptom bother score from 3.4 to 7.0, p = 0.0001. CONCLUSIONS: The multimodal treatment was more effective and TENS alone or in association presented longer lasting results for improvement of clinical symptoms of OAB and QoL.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Marc Tellenbach; Marc Schneider; Livio Mordasini; George N Thalmann; Thomas M Kessler Journal: World J Urol Date: 2012-05-24 Impact factor: 4.226
Authors: Pamela J Levin; Jennifer M Wu; Amie Kawasaki; Alison C Weidner; Cindy L Amundsen Journal: Int Urogynecol J Date: 2012-03-13 Impact factor: 2.894
Authors: Patricia S Goode; Kathryn L Burgio; Julie L Locher; Mary G Umlauf; L Keith Lloyd; David L Roth Journal: J Am Geriatr Soc Date: 2002-05 Impact factor: 5.562
Authors: Scott A MacDiarmid; Kenneth M Peters; S Abbas Shobeiri; Leslie S Wooldridge; Eric S Rovner; Fah Che Leong; Steven W Siegel; Susan B Tate; Brian A Feagins Journal: J Urol Date: 2010-01 Impact factor: 7.450
Authors: Fiona Stewart; Luis F Gameiro; Regina El Dib; Monica O Gameiro; Anil Kapoor; Joao L Amaro Journal: Cochrane Database Syst Rev Date: 2016-12-09